Excessive immune response disorders such as arthritis result from a functional increase in the activity of the immune system. Autoimmunity and hypersensitivity are types of excessive immune response disorders. They are often related, and both may be present in patients with excessive immune responses. The cause of immune system overreactions is poorly understood. Interplay between genetic factors, particularly major histocompatibility (MHC) complex genes, and environmental factors are thought to be important in the development of autoimmune disorders.
Some evidence suggests that excessive immune responses may be due to glucocorticoid resistance in target tissues. For example, the number of glucocorticoid receptors in circulating leukocytes is decreased 50% in patients with RA. This decrease in receptors would prevent adequate suppression of leukocyte activity and could further enhance inflammation.Rheumatologists remain the most up-to-date health professionals in autoimmune disease treatment. Early intervention has been noted by nearly all in the field as the single most important factor in treatments and continued quality of life. New advancements in risk factors, diagnosis, and therapies have made it possible for rheumatologist to treat these conditions successfully with the best possible outcomes.
Successful treatment of autoimmune diseases have resulted from a growing array of therapies available to specialists. Symptomatic treatments have traditionally been used for patients with rheumatoid arthritis, lupus and other autoimmune disorders. While these treatments are still used regularly, new disease-modifying therapies have produced the most impressive results in treating these diseases. Additionally, combination therapies continue to grow in preference and offer exciting results in disease management.
Some evidence suggests that excessive immune responses may be due to glucocorticoid resistance in target tissues. For example, the number of glucocorticoid receptors in circulating leukocytes is decreased 50% in patients with RA. This decrease in receptors would prevent adequate suppression of leukocyte activity and could further enhance inflammation.Rheumatologists remain the most up-to-date health professionals in autoimmune disease treatment. Early intervention has been noted by nearly all in the field as the single most important factor in treatments and continued quality of life. New advancements in risk factors, diagnosis, and therapies have made it possible for rheumatologist to treat these conditions successfully with the best possible outcomes.
Successful treatment of autoimmune diseases have resulted from a growing array of therapies available to specialists. Symptomatic treatments have traditionally been used for patients with rheumatoid arthritis, lupus and other autoimmune disorders. While these treatments are still used regularly, new disease-modifying therapies have produced the most impressive results in treating these diseases. Additionally, combination therapies continue to grow in preference and offer exciting results in disease management.
All reports in Rheumatology/Arthritis
|
Rheumatoid Arthritis – Pipeline Review, H1 2012
2/27/2012 | published by: Global Markets Direct
... for Rheumatoid Arthritis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Rheumatoid Arthritis. 'Rheumatoid Arthritis - Pipeline Review, H1 2012' ...
|
more...
|
$500.00
|
|
China Rheumatoid Arthritis Prescription Drug Sales Data 2006-2010
11/1/2011 | published by: Draco Healthcare Consulting LLC
... and drug purchasing data from extensive hospital coverage in 16 major cities and more than 300 hospitals. Sampled hospitals are from major Chinese cities across different geographic locations, including Beijing, Shanghai, Guangzhou, Nanjing, Chengdu, Chongqing, ...
|
more...
|
$8,000.00
|
|
Rheumatoid Arthritis Therapeutics - Pipeline Assessment and Market Forecasts to 2018
10/1/2011 | published by: GlobalData
... is an essential source of information and analysis on the global rheumatoid arthritis therapeutics market. The report identifies the key trends shaping and driving the global rheumatoid arthritis therapeutics market. The report also provides insights ...
|
more...
|
$3,500.00
|
|
Rheumatoid Arthritis - Pipeline Review, H2 2011
9/28/2011 | published by: Global Markets Direct
... for Rheumatoid Arthritis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Rheumatoid Arthritis. 'Rheumatoid Arthritis - Pipeline Review, H2 2011' ...
|
more...
|
$500.00
|
|
Rheumatoid Arthritis Market Forecast
9/8/2011 | published by: Datamonitor
... market players, but the growing enthusiasm for non-TNF biologics at earlier lines of therapy is predicted to continue over the next decade and serves as an additional growth driver. Gain insight into the RA competitive ...
|
more...
|
$15,200.00
|
|
Rheumatoid Arthritis Market Forecast
9/8/2011 | published by: Datamonitor
... oral drugs and reformulations of current brands are expected to fuel growth across the seven major markets, rising from $12bn in 2010 to $18bn by 2020. TNF inhibitors will remain dominant market players, but the ...
|
more...
|
$15,200.00
|
|
Market and Product Forecasts: Disease Modification in Rheumatoid Arthritis – Novel therapies plus reformulations poised to enter the market
9/8/2011 | published by: Datamonitor
... launch of novel oral drugs and reformulations of current brands are expected to fuel growth across the seven major markets, rising from $12bn in 2010 to $18bn by 2020. TNF inhibitors will remain dominant market ...
|
more...
|
$11,400.00
|
|
Market and Product Forecasts: Disease Modification in Rheumatoid Arthritis - Novel therapies plus reformulations poised to enter the market
9/8/2011 | published by: Datamonitor
... market players, but the growing enthusiasm for non-TNF biologics at earlier lines of therapy is predicted to continue over the next decade and serves as an additional growth driver.Gain insight into the RA competitive landscape ...
|
more...
|
$11,400.00
|
|
Rheumatoid Arthritis: World Drug Market 2011-2021
9/7/2011 | published by: Visiongain
... levels. Through our research and analysis we aim to save you time and help in your decisions. See how drugs such as Celebrex, Arcoxia, Humira, Remicade, Enbrel, MabThera and Cimzia can perform to 2021, finding ...
|
more...
|
$2,642.00
|
|
R&D Trends: Rheumatoid Arthritis - Approaching an era of novel kinase inhibitors
7/1/2011 | published by: Datamonitor
... Notably, opinion leaders remain hopeful about Pfizer’s tofacitinib (formerly tasocitinib), a Janus kinase (JAK) inhibitor, despite four reported deaths in a Phase III study. Features and benefits Support R&D decision making by evaluating the competitive ...
|
more...
|
$3,800.00
|
|
Specialty Pharmaceutical Industry - 2011 Yearbook
5/24/2011 | published by: GBI Research
... niche indications, namely: Human Immunodeficiency Virus (HIV)/Acquired immune deficiency syndrome (AIDS), age related macular degenerative disorders, attention deficit hyperactivity disorder (ADHD), Alzheimer’s disease, colorectal cancer, rheumatoid arthritis, epilepsy and glaucoma, including their annual cost of ...
|
more...
|
$3,500.00
|
|
Osteoarthritis (OA) Pain Therapeutics - Pipeline Assessment and Market Forecasts to 2017
5/3/2011 | published by: GlobalData
... The report is an essential source of information and analysis on the global Osteoarthritis pain Therapeutics market. The report identifies the key trends shaping and driving the global Osteoarthritis pain Therapeutics market. The report also ...
|
more...
|
$2,000.00
|
|
U.S. Rheumatoid Arthritis Market: Assessment of Biologics and New Treatments
5/2/2011 | published by: Frost & Sullivan
... patient forecasts. Market challenges, drivers, and restraints are identified and assessed. Strategic recommendations are presented to overcome listed industry challenges. This research service does not include market revenue forecasts for DMARDs. This research service highlights ...
|
more...
|
$6,000.00
|
|
Osteoarthritis Pain Therapeutics - Pipeline Assessment and Market Forecasts to 2017
5/1/2011 | published by: GlobalData
... is an essential source of information and analysis on the global osteoarthritis pain market. The report identifies the key trends shaping and driving the global osteoarthritis pain market. The report also provides insights on the ...
|
more...
|
$2,000.00
|
|
Gout Therapeutics Market to 2017- Entry of Novel Therapies such as Krystexxa, Uloric, Adenuric and Colcrys to Drive Market
4/1/2011 | published by: GBI Research
... Novel Therapies such as Krystexxa, Uloric, Adenuric and Colcrys to Drive Market”, which provides insights into gout therapeutics sales and price forecasts until 2017. The report also delves deep into global gout treatment usage patterns. ...
|
more...
|
$3,500.00
|
|
Juvenile Rheumatoid Arthritis (JRA) Therapeutics - Pipeline Assessment and Market Forecasts to 2017
4/1/2011 | published by: GlobalData
... to 2017”. The report is an essential source of information and analysis on the global JRA therapeutics market. The report identifies the key trends shaping and driving the global JRA therapeutics market. The report also ...
|
more...
|
$2,000.00
|
|
Epidemiology: Rheumatoid Arthritis
3/18/2011 | published by: Datamonitor
... markets (US, Japan, France, Germany, Italy, Spain, and the UK). More than half of rheumatoid arthritis cases in the seven major markets (2.6 million) in 2010 were in the US alone. Datamonitor es Features and ...
|
more...
|
$5,700.00
|
|
Gout Therapy Area Pipeline Report
3/14/2011 | published by: Life Science Analytics (LSA)
... a summary of the latest news and developments in this area. Scope of the report: Each Life Science Analytics’ Therapy Area Pipeline Report provides the user with real detail on drug pipelines, by company and ...
|
more...
|
$1,495.00
|
|
Osteoarthritis Therapy Area Pipeline Report
3/14/2011 | published by: Life Science Analytics (LSA)
... a summary of the latest news and developments in this area. Scope of the report: Each Life Science Analytics’ Therapy Area Pipeline Report provides the user with real detail on drug pipelines, by company and ...
|
more...
|
$1,495.00
|
|
Rheumatoid Arthritis Therapy Area Pipeline Report
3/14/2011 | published by: Life Science Analytics (LSA)
... as well as a summary of the latest news and developments in this area. Scope of the report: Each Life Science Analytics’ Therapy Area Pipeline Report provides the user with real detail on drug pipelines, ...
|
more...
|
$1,495.00
|
|
Paget's Disease Therapy Area Pipeline Report
3/14/2011 | published by: Life Science Analytics (LSA)
... as well as a summary of the latest news and developments in this area. Scope of the report: Each Life Science Analytics’ Therapy Area Pipeline Report provides the user with real detail on drug pipelines, ...
|
more...
|
$1,495.00
|
|
Gout Therapeutics - Pipeline Assessment and Market Forecasts to 2017
3/1/2011 | published by: GlobalData
... essential source of information and analysis on the global gout market. The report identifies the key trends shaping and driving the global gout market. The report also provides insights on the prevalent competitive landscape and ...
|
more...
|
$2,000.00
|
|
Gout - Pipeline Review, Q1 2011
2/28/2011 | published by: Global Markets Direct
... with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Gout. 'Gout - Pipeline Review, Q1 2011' is built using data and information ...
|
more...
|
$500.00
|
|
Rheumatoid Arthritis - Pipeline Review, Q1 2011
2/28/2011 | published by: Global Markets Direct
... for Rheumatoid Arthritis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Rheumatoid Arthritis. 'Rheumatoid Arthritis - Pipeline Review, Q1 2011' ...
|
more...
|
$500.00
|
|
Rheumatoid Arthritis Therapy Pipeline Report
1/6/2011 | published by: Life Science Analytics (LSA)
... drugs by company and by stage as well as a summary of the latest news and developments in this area. Scope of the report: Each Life Science Analytics’ Therapy Area Pipeline Report provides the user ...
|
more...
|
$1,495.00
|


